Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cariprazine Flexible Dose · 1 trial · 3 indications
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (i.e. laboratory value), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. A TEAE is an AE that occurs or worsens after receiving study drug.
Clinical laboratory parameters included tests of hematology, chemistry, urinalysis and prolactin. The investigator assessed the results for clinical significance.
Vital sign parameters included blood pressure, pulse rate, body mass index (BMI), weight, and waist circumference. The investigator assessed the results for clinical significance.
A standard 12-lead ECG was performed. The investigator determined the clinical significance of the ECG findings using the central ECG interpretation laboratory report.
C-SSRS is a clinician-rated scale that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 "wish to be dead," and 5 "active suicidal ideation with specific plan and intent". Suicidal behavior is classified on a 5-item scale: 0 "no suicidal behavior, and 4 "actual attempt".
AIMS assesses abnormal involuntary movements, such as tardive dyskinesia, associated with antipsychotic drugs; it measures facial, oral, extremities, and trunk movements, as well as the participant's awareness of abnormal movements. The first 10 items are rated on a none (0) to severe (4) scale. There are an additional 2 items on dental status that are answered yes or no.
BARS is a 4-item rating scale used to assess drug-induced akathisia. The scale comprises items for rating the observable restless movements that characterize the condition, the subjective awareness of restlessness, and any distress associated with the akathisia (each on a 4-point scale from normal \[0\] to severe \[3\]). In addition, there is a global severity for akathisia rated on a 6-point scale (absent \[0\] to severe akathisia \[5\]).
SAS is a 10-item rating scale for assessment of antipsychotic-induced parkinsonism in both clinical practice and research settings. Each item ranges from 0 (normal) to 4 (extreme symptoms). The scale consists of 1 item measuring gait (hypokinesia), 6 items measuring rigidity, and 3 items measuring glabella tap, tremor, and salivation, respectively.
Ocular examination parameters included Intraocular pressure (IOP) measurement, Best-corrected visual acuity (BCVA), color fundus photography, color vision testing using Hardy Rand and Rittler (HRR) plates, and assessment of Optical coherence tomography (OCT) and cataracts. The investigator assessed the results for clinical significance.
| Arm | Type | Description |
|---|---|---|
| Cariprazine Dose 1 | EXPERIMENTAL | Participants with Schizophrenia (age 13 to 17 years and \< 40 kg body weight) will receive cariprazine. |
| Cariprazine Dose 2 | EXPERIMENTAL | Participants with Schizophrenia (age 13 to 17 years and \>= 40 kg body weight) will receive cariprazine. |
| Cariprazine Dose 3 | EXPERIMENTAL | Participants with Bipolar I Disorder (age 10 to 12 years and \<40 kg body weight) will receive cariprazine. |
| Cariprazine Dose 4 | EXPERIMENTAL | Participants with Bipolar I Disorder (age 10 to 12 years and \>= 40 kg body weight) will receive cariprazine. |
| Cariprazine Dose 5 | EXPERIMENTAL | Participants with Bipolar I Disorder (age 13 to 17 years and \< 40 kg body weight) will receive cariprazine. |
| Cariprazine Dose 6 | EXPERIMENTAL | Participants with Bipolar I Disorder (age 13 to 17 years and \>= 40 kg body weight) will receive cariprazine. |
| Cariprazine Dose 7 | EXPERIMENTAL | Participants with Autism Spectrum Disorder ( age 5 to 9 years) will receive cariprazine. |
| Cariprazine Dose 8 | EXPERIMENTAL | Participants with Autism Spectrum Disorder (age 10 to 12 years and \<40 kg weight) will receive cariprazine. |
| Cariprazine Dose 9 | EXPERIMENTAL | Participants with Autism Spectrum Disorder (age 10 to 12 years and \>=40 kg body weight) will receive cariprazine. |
| Cariprazine Dose 10 | EXPERIMENTAL | Participants with Autism Spectrum Disorder (age 13 to 17 years and \<40 kg weight) will receive cariprazine. |
| Cariprazine Dose 11 | EXPERIMENTAL | Participants with Autism Spectrum Disorder (age 13 to 17 years and \>= 40 kg body weight) will receive cariprazine. |
| Name | Type | Description |
|---|---|---|
| Cariprazine Flexible Dose | DRUG | 1 capsule to be taken orally at approximately the same time of day (morning or evening) |
Inclusion Criteria: * Participants with Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) primary diagnosis of schizophrenia or bipolar I disorder, or autism spectrum disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for S...
Top 15 of 16 competitors
Cariprazine Flexible Dose is being studied in schizophrenia, a psychiatric disorder. The Phase 3 program also evaluated flexible-dose cariprazine in pediatric participants with schizophrenia, bipolar I disorder, or autism spectrum disorder. It is a small molecule developed by AbbVie Inc. as a modulator of the dopamine D2 and D3 receptors.
Cariprazine Flexible Dose targets the dopamine D2 receptor (DRD2) and the dopamine D3 receptor (DRD3). It acts as a modulator at these receptors. This target profile is central to its development in schizophrenia and other psychiatric conditions.
Cariprazine Flexible Dose is developed by AbbVie Inc., which trades under the ticker ABBV. AbbVie is the company responsible for the clinical program evaluating this flexible-dose formulation.
Cariprazine Flexible Dose is in Phase 3 clinical development. It is an investigational small molecule and has not been approved by the FDA for the studied indications. The Phase 3 trial has been completed.
Cariprazine Flexible Dose has been evaluated in one completed Phase 3 trial, NCT04578756. This open-label, flexible-dose study assessed long-term safety and tolerability in pediatric participants with schizophrenia, bipolar I disorder, or autism spectrum disorder. It enrolled 310 participants across the United States and Puerto Rico.